BridgeBio Pharma (BBIO) Non-Current Deferred Tax Liability (2020)

BridgeBio Pharma has reported Non-Current Deferred Tax Liability for 1 years, with the latest figure at $1.1 million in Q4 2020.

• Quarterly Non-Current Deferred Tax Liability changed N/A year-over-year to $1.1 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $1.1 million (changed N/A YoY) and the FY2020 annual result came in at $1.1 million, changed N/A from the prior year.
• Non-Current Deferred Tax Liability held at $1.1 million in Q4 2020 per BBIO's latest filing.
• Over five years, Non-Current Deferred Tax Liability peaked at $1.1 million in Q4 2020 and troughed at $1.1 million in Q4 2020.